Advances in immunotherapy in cervical cancer.
Juan-Francisco GrauLorena Farinas-MadridCarmen Garcia-DuranDavid Garcia-IllescasAna OakninPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)
Cervical cancer represents a major public health problem, being the fourth most common cancer in incidence and mortality in women worldwide. Patients with recurrent, persistent, or metastatic disease unsuitable for curative therapeutic approaches have a dismal prognosis. Until recently, these patients were only candidates for cisplatin-based chemotherapy plus bevacizumab. However, the introduction of immune checkpoint inhibitors has revolutionized the treatment of this disease, achieving historical overall survival improvements in both the post-platinum and front-line settings. Interestingly, the clinical development of immunotherapy in cervical cancer is currently advancing to the locally advanced setting, although preliminary efficacy outcomes in this setting have been disappointing so far. Moreover, promising data are emerging from early-phase trials on novel immunotherapy approaches, such as human papillomavirus therapeutic vaccines and adoptive cell therapy. This review summarizes the main clinical trials carried out in the field of immunotherapy in the last several years.
Keyphrases
- cell therapy
- locally advanced
- public health
- clinical trial
- squamous cell carcinoma
- rectal cancer
- end stage renal disease
- stem cells
- ejection fraction
- risk factors
- newly diagnosed
- prognostic factors
- mesenchymal stem cells
- neoadjuvant chemotherapy
- chronic kidney disease
- small cell lung cancer
- polycystic ovary syndrome
- cardiovascular events
- randomized controlled trial
- phase ii study
- electronic health record
- coronary artery disease
- metabolic syndrome
- young adults
- insulin resistance
- big data
- data analysis
- type diabetes
- patient reported
- smoking cessation